NovaBay CEO steps down amid restructuring; Ipsen partners up in endocrinology;

@FierceBiotech: UCSD team targeting new stress pathway in Alzheimer's program. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: The Brent Saunders argument that he's opposed to R&D is a bit specious. $AGN acquires late-stage assets, avoids discovery. Not anti-research. | Follow @JohnCFierce

> NovaBay ($NBY) CEO Ron Najafi is leaving the company as it works to salvage some value following repeated clinical failures for its lead drug. More

> Ipsen has partnered up with Japan's Interprotein to develop new large-molecule therapies in endocrinology, focusing on Cushing's disease. News

> PTC Therapeutics ($PTCT) wrapped up enrollment on a Phase III trial of its lead drug, ataluren, in patients with a form of cystic fibrosis. Item

Medical Device News

@FierceMedDev: The top women in medical devices 2015. Feature | Follow @FierceMedDev

@VarunSaxena2: RetroSense bags $6M in funding for its viral vector gene therapy candidate for a rare eye condition. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Invitae builds out cancer and epilepsy testing menus; Illumina gets in on autism research. More | Follow @EmilyWFierce

> Diabetes duodenal resurfacing startup Fractyl bumps Series C up to $57M. More

> Teva teams up with University College London for brain imaging study. Story

> Torax Medical earns key reimbursement code for its implant to treat gastric reflux. Article

Pharma News

@FiercePharma: Zoetis ups the ante in prevention with new flu vaccine and flea fighter for dogs. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Baxalta Singapore plant gets FDA OK to produce Advate. Article | Follow @EricPFierce

> Adapt's new bargain-priced OD antidote enters contentious market. News

> Post-AASLD, Gilead's lead in hep C looks as solid as ever: analysts. Item

> Express Scripts rolls out value-based pricing for cancer meds. Report

CRO News

> WuXi lands a lead role in Genomics England's big project. Item

> Parexel touts its IT-enabled R&D services amid company shakeup. Report

> Fast-growing Charles River trades $36M for a drug discovery outfit. Article

> PRA expands in Singapore with eyes on Asian growth. Story

Pharma Manufacturing News

> Merck KGaA JV set to start producing drugs in remote Algerian village. More

> Shortages, shifts in sterile injectable market lead some prices to soar. Story

> Drug distributor recalls anxiety drug after wrong med found in a bottle. Report

> With pharma cargo theft on the rise, Thanksgiving can be a risky holiday. Item

> Hikma says FDA has closed out warning letter for EU injectables plant. Article

Pharma Asia News

> India's Supreme Court wants stricter oversight of MSD, GSK HPV clinical trials. More

> Price controls loom for generic drugs in India next year. Report

> Samsung Bioepis biosimilar may get nod in Europe. Story

> Mundipharma licenses Spectrum's NHL treatment, picks up Japan affiliate. Item

> GSK beefing up vaccine business in India. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.